我們已在上線！進一步了解

Xeris Biopharma Holdings

XERS

市值 US$18.8億

10.31 USD

+0.24

2.38%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

10.29

-0.02

0.19%

1天

2.38%

5天

-1.53%

1個月

32.52%

3個月

18.64%

6個月

68.46%

今年迄今

40.27%

1年

12.8%

5年

451.34%

10年

-49.01%

關於： Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

員工： 435

醫療保健藥品製造商－特殊及學名藥

新聞

正面

中性

負面

市場情緒 3個月

正面 25%

中性 75%

負面 0%

Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings

CHICAGO--(BUSINESS WIRE)--XERIS BIOPHARMA REINFORCES LEADERSHIP IN ENDOCRINOLOGY WITH DATA DISCLOSURES SPANNING COMMERCIAL PORTFOLIO & PIPELINE AT MULTIPLE SCIENTIFIC MEETINGS.

Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on October 1, 2026, the Compensation Committee of Xeris' Board of Directors granted non-qualified stock options and restricted stock units for an aggregate of 352,170 shares of its common stock to 60 new employees under Xeris' Inducement Equity Plan.

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Lundbeck expresses interest in buying Xeris, Bloomberg News reports

Danish drugmaker H Lundbeck A/S has expressed interest in acquiring Chicago-based Xeris Biopharma , Bloomberg News reported ‌on Tuesday, citing people familiar with the matter.

Lundbeck expresses interest in buying Xeris, Bloomberg News reports

Xeris Biopharma Holdings, Inc. (XERS) Discusses XP-8121 Program Overview, Phase 3 Study Details and Commercial Strategy Transcript

Xeris Biopharma Holdings, Inc. (XERS) Discusses XP-8121 Program Overview, Phase 3 Study Details and Commercial Strategy Transcript

Xeris Biopharma Holdings, Inc. (XERS) Discusses XP-8121 Program Overview, Phase 3 Study Details and Commercial Strategy Transcript

Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, will host an XP-8121 Program Overview today at 10 a.m. ET detailing a comprehensive clinical development strategy, including Cornerstone, its Phase 3 registrational study design, as well as the commercial opportunity for XP-8121, its investigational once-weekly sub.

Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism

Xeris Announces Details for XP-8121 Program Overview Webinar

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced details for a dedicated Program Overview webinar for XP-8121, the Company's Phase 3-ready, once-weekly subcutaneous levothyroxine injection in development for the treatment of hypothyroidism. The XP-8121 webinar will take place on Wednesday, Septemb.

Xeris Announces Details for XP-8121 Program Overview Webinar

Xeris Biopharma: A Commercial Stage Pharma That May Be A Slow-Burn Buy Opportunity

Xeris Biopharma Holdings, Inc. achieved record 2024 revenues of $203M, up 24%, with robust growth across all three commercial products. 2025 revenue guidance of $255M–$275M implies 30% growth for XERS at midpoint, supporting a forward P/S ratio of ~3.4x and fair valuation. XP-8121, a once-weekly injectable levothyroxine, targets a $1B+ U.S. market and could be a future blockbuster pending Phase 3 trial initiation.

Xeris Biopharma: A Commercial Stage Pharma That May Be A Slow-Burn Buy Opportunity

Xeris Biopharma Q2 Earnings Call Highlights

Xeris Biopharma NASDAQ: XERS reported second-quarter total revenue of $92.1 million, up 29% from a year earlier, as net product revenue increased 34% to $91 million. The company raised the low end of its full-year 2026 revenue outlook, now forecasting total revenue of $385 million to $390 million.

Xeris Biopharma Q2 Earnings Call Highlights

Xeris Biopharma Holdings, Inc. (XERS) Q2 2026 Earnings Call Transcript

Xeris Biopharma Holdings, Inc. (XERS) Q2 2026 Earnings Call Transcript

Xeris Biopharma Holdings, Inc. (XERS) Q2 2026 Earnings Call Transcript

Zacks Investment Research

Compared to Estimates, Xeris Biopharma (XERS) Q2 Earnings: A Look at Key Metrics

The headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Compared to Estimates, Xeris Biopharma (XERS) Q2 Earnings: A Look at Key Metrics

查看新聞排名

價格圖表採用Lightweight Charts™實作